Table 3

Baseline values and least squares mean changes from baseline at weeks 12 and 52 for SF-36 domain scores. 

Baseline mean (SD)Week 12 LSMWeek 52
LSM
SF-36 domain scoresPlacebo (n=488)Baricitinib (n=487)Adalimumab (n=330)Placebo
(n=488)
Baricitinib (n=487)Adalimumab (n=330)Baricitinib (n=487)Adalimumab (n=330)
Physical functioning32.4 (10.4)32.3 (10.2)31.6 (10.7)4.38.0***+6.8***9.9+8.4
Role physical36.3 (10.3)35.5 (10.3)34.5 (10.5)4.47.8***6.7***9.4++7.5
Bodily pain34.9 (7.7)34.6 (7.5)34.5 (8.5)4.69.1***+7.6***11.2+9.7
General health36.6 (8.6)37.3 (8.1)36.3 (8.7)3.15.4***4.5+++6.1+4.8
Vitality43.9 (10.1)43.8 (9.5)43.2 (10.5)3.96.4***5.7+++7.9+6.6
Social functioning41.3 (11.3)40.9 (11.6)40.0 (12.2)3.05.6***4.4*6.6++4.6
Role emotional41.4 (12.5)41.4 (12.5)40.3 (12.9)3.75.1*4.86.6+5.3
Mental health42.9 (11.3)43.3 (11.1)42.5 (11.5)3.74.03.95.14.4
  • *p≤0.05, **p≤0.01, ***p≤0.001 versus placebo.

  • + p≤0.05,++p≤0.01,+++p≤0.001 versus adalimumab.

  • LSM, least squares mean; SF-36, Short-Form-36.